Popular Articles

American Career College's Ontario Campus Approved To Offer Respiratory Therapy Program
American Career College has gained approval to offer a Respiratory Therapy (RT) program at its Ontario campus, where the program"s initial class will commence on July 20, 2009. Currently, American Career College offers an RT program at its Orange County campus in Anaheim.
drugs without prescription
Pfizer Discontinues SUN 1094 Trial Of Sunitinib Plus Paclitaxel In Advanced Breast Cancer
Pfizer Inc announced the discontinuation of the SUN 1094 Phase 3 study that evaluated SUTENT® (sunitinib malate) plus paclitaxel versus bevacizumab plus paclitaxel for the first line treatment of patients with advanced breast cancer. The independent Data Monitoring Committee (DMC) found that treatment with sunitinib in combination with paclitaxel would be unable to meet the primary endpoint of superior progression-free survival (PFS) compared to the combination of bevacizumab and paclitaxel. No new safety issues were identified.
News of the day
ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented At ASCO
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced the presentation of encouraging trastuzumab-DM1 (T-DM1) clinical data at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Orlando, Florida.
Diagnostics

LSUHSC Research On How Like Cell Receptor Systems Determine Very Different Functions, Supported By Grant

Andy Catling, PhD, Associate Professor in the Department of Pharmacology and the Stanley S. Scott Cancer Center at LSU Health Sciences Center New Orleans, has been awarded a $177, 500 supplement to his RO1 grant by the National Institute of General Medical Sciences to support his research on the mechanism by which seemingly similar cell receptor systems determine quite different functions influenced by hormones and drugs. "We are interested in how the generic ERK signaling pathway confers specific physiological outcomes such as proliferation, differentiation and cell migration," notes Dr. Catling. "We hypothesize that specificity is conferred by the action of input- and output-specific "scaffolding" molecules that assemble the pathway around growth factor receptors." The supplement was funded through the American Recovery and Reinvestment Act and will be used to help retain key personnel needed to identify and characterize ERK phosphorylation targets - proteins to which phosphate groups can be added, increasing or decreasing protein function - specified by the scaffold. These phosphorylation targets are involved in the development of disease. Dr. Ashok Pullikuth in Catling"s lab has recently identified a protein that functions in the intracellular movement and cell division activity of growth factor receptors as a novel phosphorylation target. Understanding this novel mechanism might be important in treating conditions that are dependent upon specific growth factor receptors, like some breast cancers in which the EGF receptor family drives growth and survival. "Our studies might provide insight into how specific functions of a pathway might be targeted therapeutically while not eliminating all essential housekeeping functions of the pathway," Dr. Catling says. "The beauty of research is that no one knows just how useful their findings will be in the future - there may be entirely unexpected benefits in addition to more predictable outcomes." These key personnel and the data they generate are essential to submit a competitive renewal of this RO1 grant in November. Leslie Capo Louisiana State University Health Sciences Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):